Skip to content
Mipomersen
Kynamro (mipomersen) is an oligonucleotide pharmaceutical. Mipomersen was first approved as Kynamro on 2013-01-29. It is used to treat familial combined hyperlipidemia in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
hereditary congenital and neonatal diseases and abnormalitiesD009358
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Mipomersen sodium
Tradename
Company
Number
Date
Products
KYNAMROKastle TherapeuticsN-203568 DISCN2013-01-29
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
kynamroNew Drug Application2017-01-17
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
familial combined hyperlipidemiaEFO_0000492D006950E78.49
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Mipomersen Sodium, Kynamro, Kastle Theraps Llc
75111312027-01-29DP
71019932023-09-05DP
70153152023-03-21DP
ATC Codes
C: Cardiovascular system drugs
— C10: Lipid modifying agents
— C10A: Lipid modifying agents, plain
— C10AX: Other lipid modifying agents in atc
— C10AX11: Mipomersen
HCPCS
No data
Clinical
Clinical Trials
224 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Acne vulgarisD000152EFO_0003894L703456119
SchizophreniaD012559EFO_0000692F201—26211
RosaceaD012393L712421—8
PeriodontitisD010518EFO_0000649K05.3——2316
Ischemic strokeD000083242121216
Psychotic disordersD011618F20.812211—5
Bipolar disorderD001714EFO_0000289F30.9——2215
StrokeD020521EFO_0000712I63.92111—4
HypertensionD006973EFO_0000537I101211—4
Chronic periodontitisD055113EFO_0006343K05.3——13—4
Show 16 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
DepressionD003863F33.9—11—24
PneumothoraxD011030J93.11—13—14
Major depressive disorderD003865EFO_0003761F22111——3
Multiple sclerosisD009103EFO_0003885G35—12——3
InflammationD007249211——3
Amyotrophic lateral sclerosisD000690EFO_0000253G12.21—11——2
Rheumatoid arthritisD001172EFO_0000685M06.9——2——2
Periodontal diseasesD010510K05.6——1—12
Spinal cord injuriesD013119EFO_1001919111——2
Peri-implantitisD057873EFO_1001390——2——2
Show 12 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Fragile x syndromeD005600Q99.211——24
AsthmaD001249EFO_0000270J45—3———3
Macular edemaD00826922——13
AlcoholismD000437EFO_0003829F10.131———3
Cognitive dysfunctionD060825G31.8421———3
Cerebral hemorrhageD00254332———3
Hiv infectionsD015658EFO_0000764B2012——13
Meibomian gland dysfunctionD000080343H02.88—1——12
Retinal vein occlusionD012170EFO_1001157H34.8122———2
Relapsing-remitting multiple sclerosisD020529EFO_0003929—2———2
Show 47 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—6———410
Autism spectrum disorderD000067877F84.02————2
Acute kidney injuryD058186HP_0001919N171———12
AneurysmD000783HP_0002617I72.91————1
Arteriovenous malformationsD0011651————1
Periapical periodontitisD010485EFO_1001391K04.51————1
Substance-related disordersD019966EFO_0003890F131————1
SyndromeD0135771————1
Alcohol-related disordersD019973F101————1
Chemically-induced disordersD0644191————1
Show 8 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C80————11
Gram-negative bacterial infectionsD016905————11
PainD010146EFO_0003843R52————11
Opioid-related disordersD009293EFO_0005611F11————11
AffectD000339————11
ObesityD009765EFO_0001073E66.9————11
Diabetic nephropathiesD003928EFO_0000401————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMIPOMERSEN
INNmipomersen
Description
Mipomersen (INN; trade name Kynamro) is a drug used to treat homozygous familial hypercholesterolemia and is administered by subcutaneous injection. There is a serious risk of liver damage from this drug and it can only be prescribed in the context of a risk management plan.
Classification
Oligonucleotide
Drug classantisense oligonucleotides
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COCCO[C@H]1[C@@H](O)[C@H](COP(=O)(O)S[C@H]2[C@H](COP(=O)(O)S[C@H]3[C@H](COP(=O)(O)S[C@H]4[C@H](COP(=O)(O)S[C@H]5[C@@H](OCCOC)[C@H](n6cnc7c(=O)[nH]c(N)nc76)O[C@@H]5COP(=O)(O)S[C@H]5C[C@H](n6cc(C)c(N)nc6=O)O[C@@H]5COP(=O)(O)S[C@H]5C[C@H](n6cc(C)c(=O)[nH]c6=O)O[C@@H]5COP(=O)(O)S[C@H]5C[C@H](n6cc(C)c(=O)[nH]c6=O)O[C@@H]5COP(=O)(O)S[C@H]5C[C@H](n6cc(C)c(N)nc6=O)O[C@@H]5COP(=O)(O)S[C@H]5C[C@H](n6cnc7c(=O)[nH]c(N)nc76)O[C@@H]5COP(=O)(O)S[C@H]5C[C@H](n6cc(C)c(=O)[nH]c6=O)O[C@@H]5COP(=O)(O)S[C@H]5C[C@H](n6cc(C)c(N)nc6=O)O[C@@H]5COP(=O)(O)S[C@H]5C[C@H](n6cc(C)c(=O)[nH]c6=O)O[C@@H]5COP(=O)(O)S[C@H]5C[C@H](n6cnc7c(=O)[nH]c(N)nc76)O[C@@H]5COP(=O)(O)S[C@H]5C[C@H](n6cnc7c(N)ncnc76)O[C@@H]5COP(=O)(O)S[C@H]5[C@@H](OCCOC)[C@H](n6cc(C)c(N)nc6=O)O[C@@H]5COP(=O)(O)S[C@H]5[C@@H](OCCOC)[C@H](n6cc(C)c(=O)[nH]c6=O)O[C@@H]5COP(=O)(O)S[C@H]5[C@@H](OCCOC)[C@H](n6cc(C)c(N)nc6=O)O[C@@H]5COP(=O)(O)S[C@H]5[C@@H](OCCOC)[C@H](n6cc(C)c(N)nc6=O)O[C@@H]5COP(=O)(O)S[C@H]5[C@@H](OCCOC)[C@H](n6cnc7c(=O)[nH]c(N)nc76)O[C@@H]5CO)O[C@H](n5cc(C)c(N)nc5=O)[C@H]4OCCOC)O[C@H](n4cnc5c(N)ncnc54)[C@H]3OCCOC)O[C@H](n3cc(C)c(N)nc3=O)[C@H]2OCCOC)O[C@@H]1n1cc(C)c(N)nc1=O
Identifiers
PDB—
CAS-ID629167-92-6
RxCUI1367839
ChEMBL IDCHEMBL2219536
ChEBI ID—
PubChem CID44564107
DrugBankDB05528
UNII ID9GJ8S4GU0M (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,128 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
6,985 adverse events reported
View more details